NO20042502L - Farmasoytisk formulering omfattende bicalutamid - Google Patents

Farmasoytisk formulering omfattende bicalutamid

Info

Publication number
NO20042502L
NO20042502L NO20042502A NO20042502A NO20042502L NO 20042502 L NO20042502 L NO 20042502L NO 20042502 A NO20042502 A NO 20042502A NO 20042502 A NO20042502 A NO 20042502A NO 20042502 L NO20042502 L NO 20042502L
Authority
NO
Norway
Prior art keywords
bicalutamide
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
NO20042502A
Other languages
English (en)
Norwegian (no)
Inventor
Ian Derke Cockshott
Julie Kay Cahill
Nicola Frances Bateman
Neill Hugh Carman
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20042502L publication Critical patent/NO20042502L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042502A 2001-11-16 2004-06-15 Farmasoytisk formulering omfattende bicalutamid NO20042502L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
PCT/GB2002/005159 WO2003043606A1 (fr) 2001-11-16 2002-11-14 Formulation pharmaceutique comprenant du bicalutamide

Publications (1)

Publication Number Publication Date
NO20042502L true NO20042502L (no) 2004-08-09

Family

ID=20286023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042502A NO20042502L (no) 2001-11-16 2004-06-15 Farmasoytisk formulering omfattende bicalutamid

Country Status (20)

Country Link
US (1) US20050038111A1 (fr)
EP (1) EP1448168B1 (fr)
JP (1) JP2005514355A (fr)
KR (1) KR20050044468A (fr)
CN (1) CN1615122A (fr)
AR (1) AR037390A1 (fr)
AT (1) ATE350016T1 (fr)
AU (1) AU2002343024A1 (fr)
BR (1) BR0214135A (fr)
CA (1) CA2466986A1 (fr)
DE (1) DE60217390T2 (fr)
ES (1) ES2278063T3 (fr)
IL (1) IL161902A0 (fr)
MX (1) MXPA04004591A (fr)
NO (1) NO20042502L (fr)
SE (1) SE0103839D0 (fr)
TW (1) TW200406200A (fr)
UY (1) UY27539A1 (fr)
WO (1) WO2003043606A1 (fr)
ZA (1) ZA200403689B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030077042A (ko) * 2001-02-27 2003-09-29 아스트라제네카 아베 비칼루타마이드를 포함하는 약학 제제
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7226622B2 (en) * 2003-09-18 2007-06-05 Boston Scientific Scimed, Inc. Chemoablation of tissue using biodegradable, solid salt dosage forms
JP2007526913A (ja) * 2004-01-28 2007-09-20 アンドロサイエンス コーポレイション ステロイド依存性の遺伝子活性化経路の異なる段階を標的とする阻害剤の組み合わせによる抗アンドロゲン活性の増強およびその使用
CA2577852A1 (fr) * 2004-08-31 2006-03-09 Pfizer Products Inc. Posologies pharmaceutiques comportant un medicament a faible solubilite et un polymere
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
US20080161404A1 (en) * 2005-02-23 2008-07-03 Astrazeneca Ab Bicalutamide for Delivering Increasing Steady State Plasma Levels
CA2582195A1 (fr) * 2005-03-29 2006-10-05 Usv Limited Procede de fabrication de bicalutamide
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
EP2623985A1 (fr) * 2008-02-21 2013-08-07 Iris International, Inc. Procédé pour la détermination précoce d'une récurrence après une thérapie pour le cancer de la prostate
ES2855426T3 (es) * 2008-09-17 2021-09-23 Mylan Inc Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen
PL3725778T3 (pl) 2012-09-11 2021-12-20 Medivation Prostate Therapeutics Llc Preparaty enzalutamidu
CN107049972A (zh) * 2017-03-17 2017-08-18 万特制药(海南)有限公司 一种含有来曲唑固体分散体的分散片及其制备工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
EP0748220A4 (fr) * 1994-01-21 1997-09-10 Sepracor Inc Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating

Also Published As

Publication number Publication date
SE0103839D0 (sv) 2001-11-16
ES2278063T3 (es) 2007-08-01
JP2005514355A (ja) 2005-05-19
US20050038111A1 (en) 2005-02-17
ATE350016T1 (de) 2007-01-15
KR20050044468A (ko) 2005-05-12
EP1448168B1 (fr) 2007-01-03
MXPA04004591A (es) 2004-08-13
BR0214135A (pt) 2004-10-13
EP1448168A1 (fr) 2004-08-25
IL161902A0 (en) 2005-11-20
CA2466986A1 (fr) 2003-05-30
AR037390A1 (es) 2004-11-10
TW200406200A (en) 2004-05-01
AU2002343024A1 (en) 2003-06-10
DE60217390D1 (de) 2007-02-15
CN1615122A (zh) 2005-05-11
WO2003043606A1 (fr) 2003-05-30
ZA200403689B (en) 2006-06-28
DE60217390T2 (de) 2007-11-15
UY27539A1 (es) 2003-07-31

Similar Documents

Publication Publication Date Title
NO20033384L (no) Farmasoytisk formulering
NO20033785L (no) Farmasöytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
FI20011478A0 (fi) Farmaseuttinen koostumus
ITTO20010008A0 (it) Formulazione farmaceutica
NO20040125L (no) Enterale formuleringer
DK1395242T3 (da) Flydende farmaceutisk sammensætning
NO20035627D0 (no) Farmasöytisk formulering
EE200300589A (et) Ravimkoostised
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
FI20022128A (fi) Farmaseuttinen koostumus
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DK1361791T3 (da) Agrokemisk formulering
ATE369137T1 (de) Lyophilisierte formulierung enthaltend olanzapin
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
NO20015534D0 (no) Farmasöytisk blandeapparat
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
NO20041236L (no) Farmasoytisk formulering
SE0102957D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application